Get started
Work

Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Year: 2020
Type: article
Abstract: and Conclusion• In advanced CSCC patients, treatment with cemiplimab resulted in clinically meaningful reduction in pain as early as cycle 3 with maintenance of effect through cycle 12.• Improvement in global health status/HRQL was observed as early as cycle 3 with clinically meaningful improvement seen by cycle 12.• By cycle 6, the majority of patients experienced clinically meaningful improvement or stability in global health status/HRQL and functional status, while maintaining a low symptom burden.• These results further support cemiplimab as a new standard of care option in the treatment of advanced CSCC.
DOI: 10.25251/skin.4.supp.122
Authors: Michael Migden, Danny Rischin, Medha Sasane, Vera Mastey, Anna Pavlick, Chrysalyne Schmults, Zhen Chen, Alexander Guminski, Axel Hauschild, Denise Bury, Anne Lynn Chang, Guilherme Rabinowits, Sheriff Ibrahim, Israel Lowy, Matthew Fury, Siyu Li, Chieh-I Chen
Institutions: The University of Texas MD Anderson Cancer Center, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation, Sanofi (United States), Regeneron (United States), NYU Langone Health, Brigham and Women's Hospital, Harvard University, Royal North Shore Hospital, University Hospital Schleswig-Holstein, Stanford Medicine, Stanford University, Baptist Hospital of Miami, Baptist Health South Florida, University of Rochester Medicine
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: diamond
Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Merck KGaA, Les Laboratories Pierre Fabre, National Comprehensive Cancer Network, Castle Biosciences, Eisai, Astellas Pharma, Sun Pharma, Genentech
OpenAlex ID: W3103557967
FWCI: 0.538
Cites: 1
Cited by: 3
Related to: 10